---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-086939"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2026-08-10T11:15:14+00:00"
generated_at: "2026-08-10T11:20:21.434121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MoonLake Phase 3 IZAR-1 meets all endpoints; Q2 cash $537M, runway to mid-2028

## Summary
- IZAR-1 Week 16: ACR50 42.1%, ACR20 66.5%, MDA 41.2%, PASI90 61% for sonelokimab 60mg.
- Q2 2026 cash $537.0M; expects runway to mid-2028; up to $400M non-dilutive from Hercules.
- Q2 R&D expenses $50.2M vs $54.5M in Q1; G&A $11.4M vs $15.5M in Q1.
- IZAR-1 continues to Week 52; full readout H1 2027; IZAR-2 enrollment completion expected Q3 2026.
- HS BLA submission expected end Sep 2026; PDUFA date allocation and Priority Review decision end Nov 2026.

## SEC filing metadata
- accession: 0001213900-26-086939
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2026-08-10T11:15:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/0001213900-26-086939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea0301191-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-086939
- JSON: https://secwatch.observer/filing/0001213900-26-086939.json
- Plain text: https://secwatch.observer/filing/0001213900-26-086939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.